Precision Medicine Day Three


Precision 2018 Day 3

Registration opens

Beyond the genome

Precision Medicine Therapeutic Development


Chair's opening remarks


Enabling biomarker discovery in Parkinson’s disease through Integration of multi-OMICS, clinical data and artificial intelligence

  • Use of clinical proteomic, lipidomic, and metabolomic assessment of multiple biofluids for a population health biomarker assessment of Parkinson’s Disease
  • Utilization of bAIcis, a Bayesian artificial intelligence analysis approach to integrate molecular and clinical data to identify casual drivers of Parkinson’s Disease
  • Integration of a biomarker strategy for multiple clinical unmet needs

Application of precision medicine and genomics to common disease

  • How AstraZeneca are applying genomics to identify new drug targets for common disease
  • The development of complimentary diagnostics to enable precision medicine
  • Future opportunities – collaboration and partnership

Development of an integrated platform for biomarker and drug target discovery using proteomics

  • The use of innovations in MS-based technologies offers a high capacity throughput proteomic profiling for clinical biochemistry purposes that can be industrialised, as has been achieved at the Stoller Biomarker Discovery Centre
  • Markers of risk in ovarian cancer have been investigated using a SWATH MS approach. We have also identified potential new curative strategies for chronic myeloid leukaemia and polycythaemia vera
  • Combined with validation platforms, this approach offers a quicker route to mechanistic detail/drug targets plus biomarkers for risk and stratification. Linkage of proteomic data to electronic health records through safe haven health informatics allows the integration of complex molecular phenotyping with endotypic data
  • Reduction in time for biomarker development for patient benefit

A gut feeling: using microbiome manipulation to treat allergic asthma

  • Understanding the human microbiome from a system perspective
  • Leveraging clinical data to establish human-first rationale for patient stratification and drug development
  • Utilizing a rationally designed microbial consortia for the treatment and prevention of allergic asthma

10:35 Networking Break


Induced pluripotent stem cells as a workhorse for human genetic studies

  • Learn how human iPS cells are transforming the study of disease alleles
  • What are the opportunities and challenges in using iPSCs as disease models?
  • Introduction to the Human Induced Pluripotent Stem Cells Initiative (HipSci)

Probing disease mechanisms in ion-channel epilepsy using iPSCs, reprogramming and optogenetic approaches to provide personalized therapeutic approaches

  • The lack of easy accessibility to the cells of the nervous system has hampered progress towards the discovery of degenerative mechanisms as well as more effective treatments for neurological diseases
  • The ground-breaking technology of reprogramming, which allows for the generation of patient specific induced pluripotent stem cells (iPSCs) has created an unprecedented opportunity for a new approach towards developing cellular models of human disease
  • We employ this approach to generate cortical excitatory and inhibitory neurons as well as spinal motor neurons and astrocytes from individual patients
  • We use gene-editing techniques to introduce or fix mutations and then study the neurons we make by classical methods including immunocytochemistry, biochemistry, global genomic analysis, live cell imaging as well as by non-invasive electrophysiological recording techniques

Bedside to bench and back again. A real world application for personalised medicine and synthetic biology in Cardiovascular disease drug discovery.

  • An example of an integrated transcriptomic and proteomic  platform using human induced pluripotent cardiomyocytes
  • Application of machine learning and deep neural networks for candidate drug and target identification and novel targeting
  • Derivation of isogenetic lines using an efficient CRISPR -CAS9 for disease modelling and for homozygote gene correction studies

Precision medicine in healthcare


Cardiovascular pharmacology- Stratifying patients to improve efficacy and prevent toxicity of cardiovascular drugs

  • Anticoagulant and lipid lowering drugs will be discussed
  • Direct oral anticoagulants vs warfarin, efficacy and toxicity
  • Uptake of personalised therapies by healthcare systems
  • Health inequality and personalised medicine

What does good care feel like? A patient's perspective

  • What do we mean by precision medicine? 
  • Expectations, fears and hope
  • Precision - in care, treatment and communication

Stratifying patients to improve outcomes — recent advances in host biomarker approach for sepsis and tuberculosis

  • Precision medicine can benefit from validated host biomarkers
  • Validation of host protein and nucleic acid biomarkers for key public health priorities
  • Probable risk, prognosis, diagnosis, treatment response are key considerations for patient stratification
  • Recent examples of advances in biomarker discovery, validation, translational and commercial development

Actionable genes

  • The payer perspective of the genetic testing market
  • What our customers want
  • Actionable and tiering of genes
  • Commissioning of genetic tests

13:00 Networking Lunch

Closing keynotes: The future of precision medicine

Thomas Hach

Chaired by Thomas Hach, Director Healthcare Systems, Novartis International AG

Everson Nogoceke

Precision medicine strategies for common diseases

  • The prospects of Pharmacogenetics in common ophthalmic diseases
  • From Genetics and genomics to target validation in humans
  • The prospects of biomarkers based on imaging
Karina Bienfait

Precision medicine in drug development: Leveraging genetic data to inform pipeline decisions

  • Discuss implementation of routine genomic research during drug development
  • Leveraging genomic data to achieve precision medicine
  • Discuss challenges in conducting genomic research in the context of global clinical trials
Thomas Hach

Chair's closing remarks


Closing remarks from Terrapinn

15:20 End of Day 3

last published: 15/May/18 12:55 GMT




Sign Up for Event Updates

World Precision Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Joan Shutt
t/ +44 (0)207 092 1134


Issa Mauthoor
+44 (0)207 092 1257